Zanubrutinib, Alone and in Combination with Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.

Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/49502

Title:	Zanubrutinib, Alone and in Combination with Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia.
Authors:	Tam C.;Munoz J.;Cull G.;Opat S. ;Allewelt H.;Zhang X.;Stern J.C.;Hilger J.;By K.;Cohen A.;Tedeschi A.
Institution:	(Tam) Alfred Hospital and Monash University, Melbourne, VIC, Australia (Munoz) Banner MD Anderson Cancer Center, Gilbert, AZ, United States (Cull) Sir Charles Gairdner Hospital, Perth, WA, Australia (Cull) University of Western Australia, Perth, WA, Australia (Opat) Monash Health, Clayton, VIC, Australia (Opat) Monash University, Clayton, VIC, Australia (Allewelt, Zhang, Stern, Hilger, By, Cohen) BeiGene, San Mateo, CA, United States (Tedeschi) ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Issue Date:	30-Mar-2023
Copyright year:	2023
Publisher:	Wolters Kluwer Health
Place of publication:	United States
Publication information:	HemaSphere. 7(4) (pp E870), 2023. Date of Publication: 24 Apr 2023.
Journal:	HemaSphere
DOI:	http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1097/HS9.0000000000000870
URI:	https://repository.monashhealth.org/monashhealthjspui/handle/1/49502
Type:	Letter
Subjects:	chronic lymphatic leukemia tislelizumab zanubrutinib
Type of Clinical Study or Trial:	Opinion, perspective or news
Appears in Collections:	Articles

14

checked on Mar 15, 2025

Check